Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.

Aztreonam–avibactam is a promising treatment for complicated intra-abdominal infections and hospital-acquired or ...

Zaynich could play a key role in treating patients suffering from complicated urinary tract infections caused by ...

Wockhardt now intends to file a new drug application (NDA) with the USFDA and seek marketing authorisation application with ...

Shares of Wockhardt were in high demand on Monday after the company said that its drug Zaynich has achieved over 97 per cent clinical efficacy in treating critically ill patients with ...